

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspro.gov

APPLICATION NO.	FII	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/089,020	0	3/27/2003	Amarjit Singh	U 013943-5	9010
140	7590	03/20/2006		EXAMINER	
LADAS & 26 WEST 61		∓T	PRYOR, ALTON NATHANIEL		
NEW YORK				ART UNIT	PAPER NUMBER
	•			1616	

DATE MAILED: 03/20/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 10/03)

		Applicat	tion No.	Applicant(s)	Applicant(s)			
		10/089,0	020	SINGH ET AL.				
	Office Action Summary	Examine	ər	Art Unit				
		Alton N.	Pryor	1616				
Period fo	The MAILING DATE of this communic r Reply	ation appears on th	ne cover sheet	with the correspondence a	ddress -			
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MA asions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this communication for reply is specified above, the maximum stature to reply within the set or extended period for reply with the set of extended period for reply with the set of extended period for reply with the set or extended period for reply with	ILING DATE OF T 37 CFR 1.136(a). In no e ilication. tory period will apply and II, by statute, cause the ap	HIS COMMUN event, however, may a will expire SIX (6) MO oplication to become a	IICATION. a reply be timely filed  ONTHS from the mailing date of this ABANDONED (35 U.S.C. § 133).	·			
Status								
2a) <u></u>	Responsive to communication(s) filed This action is <b>FINAL</b> . 2b Since this application is in condition fo closed in accordance with the practice	)⊠ This action is r allowance excep	non-final. ot for formal ma	- ·	ne merits is			
Dispositi	on of Claims			·				
5)	Claim(s) 1,2,4-11,15,17 is/are pending 4a) Of the above claim(s) is/are Claim(s) is/are allowed. Claim(s) 1,2,4-11,15 and 17 is/are rejected to. Claim(s) is/are objected to. Claim(s) are subject to restriction on Papers The specification is objected to by the Interpretation of the drawing(s) filed on is/are: and applicant may not request that any objection	withdrawn from contected.  on and/or election  Examiner.  a) accepted or boon to the drawing(s)	onsideration. requirement.  o) □ objected to be held in abeyo	ance. See 37 CFR 1.85(a).				
44)[]:	Replacement drawing sheet(s) including the	·		• • •	• •			
-	The oath or declaration is objected to b	y the Examiner. N	lote the attache	ed Office Action or form P	TO-152.			
Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some col None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.								
2) 🔲 Notice 3) 🔯 Inform	e of References Cited (PTO-892)  of Oraftsperson's Patent Drawing Review (PTO nation Disclosure Statement(s) (PTO-1449 or PT No(s)/Mail Date 3/27/03;4/22/05.		Paper No	Summary (PTO-413) o(s)/Mail Date Informal Patent Application (PT 	'O-152)			

Application/Control Number: 10/089,020 Page 2

Art Unit: 1616

## **DETAILED ACTION**

I. Rejection of claims 1,2,4-11,15,17 under 35 USC 112, 1<sup>st</sup> paragraph in regard to "pharmaceutical composition of Nimisulide" will not be maintained. Claims have been amended to claim the "tablet composition" instead of the general "composition".

- II. Rejection of claims 1,2,4-11,15,17 under 35 USC 112, 1<sup>st</sup> paragraph with respect to "methacrylic acid derivatives" will not be maintained. The term "derivative" has been deleted from the claims.
- III. Rejection of claims 1,2,4-11,15,17 under 35 USC 112, 1<sup>st</sup> paragraph with respect to "fraction" will not be maintained. The term "fraction" has been replaced by the term "layer".
- IV. Applicant's arguments, see paper, filed 8/1/20, with respect to the rejection(s) of claim(s) 1,2,4-11,15,17 under 35 USC 112, 1<sup>st</sup> paragraph have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made below.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1,2,4-11,15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Skinhoj (WO 99/12524; 3/18/99). Skinhoj teaches a composition of an NSAID for peroral use comprising a fast release layer and an extended release layer, wherein said NSAID is present in both layers and in an amount ranging from 1 to 1600 mg. Skinhoj teaches that such a composition reduces the dose amount of active required on a daily bases as compared to a plain tablet. Skinhoj teaches that the composition can comprise a control release material such as cellulose derivatives, and excipients, plasticizers, calcium carbonate and fatty acids. Skinhoj teaches that the composition can exist in tablet form. Skinhoj teaches a number of NSAIDs including nimesulide. See abstract, page 19 line 22 – page 20 line 27, page 21 lines 19-21, page 26 lines 28-29, page 35 lines 15-24, page 36 line 25 – page 38 line 32, claims 1, 11. Skinhoj does not disclose an example where nimesulide is employed in the composition / tablet. It would have been obvious to one having ordinary skill in the art to have employed nimesulide in the tablet / composition. One would have been motivated to do this in order to decrease the dosage amount of nimesulide given to a patient.

## **Telephonic Inquiry**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton N. Pryor whose telephone number is 571-272-0621. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone

Application/Control Number: 10/089,020 Page 4

Art Unit: 1616

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Alton Pryor

Primary Examiner

AU 1616